 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Animal Model:
|
Aph1B/C KO
|
|
Preparation Type:
|
Genetic Preparations
|
|
DA-related behavior:
|
Enhanced hyperactivity in response to amphetamine
|
|
Gating:
|
PPI deficits, hypersensitive to MK-801 (increased PPI deficits)
|
|
Cognitive behavior:
|
Impaired working memory on Morris water maze
|
|
Molecular/morphological signature:
|
Enhanced DA turnover in ventral striatum; gamma-secretase
dependent cleavage of Nrg1 is impaired
|
|
Response to APD:
|
Haloperidol and clozapine reverse PPI deficits
|
|
Citations:
|
Dejaegere T, Serneels L, Schäfer MK, Van Biervliet J, Horré
K, Depboylu C, Alvarez-Fischer D, Herreman A, Willem M,
Haass C, Höglinger GU, D'Hooge R, De Strooper B. Deficiency
of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and
sensorimotor gating that can be reversed with antipsychotic
treatment. Proc Natl Acad Sci U S A . 2008 Jul 15 ;
105(28):9775-80. Abstract
|
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: